News
ARWR
22.33
-1.24%
-0.28
Hepion ends Phase 2 study for NASH drug due to cash restraints
Seeking Alpha · 15h ago
TURNSTONE BIOLOGICS APPOINTS WILLIAM WADDILL TO ITS BOARD OF DIRECTORS
Reuters · 3d ago
Weekly Report: what happened at ARWR last week (0408-0412)?
Weekly Report · 5d ago
Wolfe upgrades Ionis to outperform, cites upcoming catalysts
Seeking Alpha · 04/10 16:03
Buy Rating Affirmed for Arrowhead Pharmaceuticals Following Promising Plozasiran Trial Results
TipRanks · 04/10 13:55
Madrigal announces US launch of NASH/MASH drug Rezdiffra
Healthcare Madrigal announces US launch of NASH/MASH drug Rezdiffra. The drug is now available in the US through a specialty pharmacy network. Other companies working on therapies for NASH and MASH include Eli Lilly and Novo Nordisk. MadrigAL is the first to receive FDA approval for the treatment of the disease.
Seeking Alpha · 04/09 14:03
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Piper Sandler
TipRanks · 04/08 10:37
Weekly Report: what happened at ARWR last week (0401-0405)?
Weekly Report · 04/08 09:12
Reported Sunday, Arrowhead Pharmaceuticals Announces New Phase 2 Data Of Plozasiran Published In JAMA Cardiology And Presented At ACC.24
Benzinga · 04/08 06:54
ARROWHEAD PHARMACEUTICALS ANNOUNCES NEW PHASE 2 DATA OF PLOZASIRAN PUBLISHED IN JAMA CARDIOLOGY AND PRESENTED AT AMERICAN COLLEGE OF CARDIOLOGY 73RD ANNUAL SCIENTIFIC SESSION & EXPO
Reuters · 04/07 13:00
NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling
When insiders sell shares, it could be a preplanned sale or indicate concern in the company's prospects. Zoom Video Communications, Inc. Sold a total of 1,100 shares at an average price of $65.38. Arrowhead Pharmaceuticals Inc. And Affirm Holdings also had recent notable insider sales.
Benzinga · 04/04 11:23
Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Arrowhead Pharmaceuticals, Inc. Share price has dropped 27% in the last month. The company's price-to-sales ratio of 17.9x is higher than most other companies in the industry. Despite the drop in share price, the company's P/S is still higher than the industry average. The revenue growth forecast for the company is not in line with the expected future growth.
Simply Wall St · 04/03 10:05
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals, Inc. Granted inducement grants to 32 new employees. The company develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's Board of Directors approved the grants as an inducement to entering into employment with the Company on March 30, 2024.
Barchart · 04/01 15:30
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is largely controlled by institutional shareholders who own 63% of the company
A total of 24 investors have a majority stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) The company is owned by institutions with 63% of the company. The largest shareholder, BlackRock, Inc., owns 11% of Arrowhead pharmaceuticals. The company has a high level of insider ownership, but this doesn't mean the company is well-liked. Arrowhead Pharmas has a history of growth and is expected to grow in the years to come. It owns around US$140m worth of shares in the company .
Simply Wall St · 04/01 14:02
Weekly Report: what happened at ARWR last week (0325-0329)?
Weekly Report · 04/01 09:12
Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Arrowhead Pharmaceuticals is a drug developer focused on RNA-interference therapeutics. The company has faced setbacks and obstacles in securing commercial approval for its drugs. Partnerships with Janssen and Horizon Therapeutics have been terminated, and several drug candidates have been shelved. Arrowhead's stock price has fallen 25% since I last covered the company in 2019.
Seeking Alpha · 03/30 09:16
Weekly Report: what happened at ARWR last week (0318-0322)?
Weekly Report · 03/25 09:12
Friday 3/22 Insider Buying Report: DCTH, ARWR
NASDAQ · 03/22 17:39
Inventiva Phase 2 study for MASH drug meets primary endpoint
Inventiva Phase 2 study for MASH drug meets primary endpoint. Inventiva's drug candidate lanifibranor met its primary efficacy endpoint in the treatment of patients with MASH/NASH and type 2 diabetes. Last week, Madrigal drug Rezdiffra became the first FDA-approved treatment for the liver disorder.
Seeking Alpha · 03/18 21:45
Weekly Report: what happened at ARWR last week (0311-0315)?
Weekly Report · 03/18 09:12
More
Webull provides a variety of real-time ARWR stock news. You can receive the latest news about Arrowhead Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.